Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients
暂无分享,去创建一个
F. Fernández‐Avilés | J. S. San Miguel | S. Brunet | J. Pérez-Simón | R. Martino | L. Rosiñol | J. Sierra | A. Sureda | C. Cañizo | A. Alegre | A. Sampol | J. F. Miguel | J. Moraleda | D. Caballero | J. Petit | J. Lahuerta | A. García | J. Tomás | J. Cabrera | L. Vázquez | J. Diez‐martin | A. León | A. García | on behalf of the Gem
[1] H. Einsele,et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.
[2] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[3] H. Johnsen,et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.
[4] N. Kröger,et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] H. Einsele,et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.
[6] J. S. San Miguel,et al. Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation , 2003, British journal of haematology.
[7] M. Gold,et al. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. , 2002, Journal of immunology.
[8] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[9] G. Gahrton,et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.
[10] G. Martinelli,et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Siebert,et al. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. , 1996, Blood.
[12] A. Grañena,et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. , 1991, The New England journal of medicine.
[13] M. Gobbi,et al. [Allogeneic bone marrow transplantation in multiple myeloma]. , 1991, Haematologica.
[14] K. Nilsson,et al. Establishment and characteristics of two unique cell lines from patients with lymphosarcoma , 1974, International journal of cancer.